[8-K] X4 Pharmaceuticals, Inc. Reports Material Event
X4 Pharmaceuticals completed two related private placements that raised aggregate gross proceeds of $85,000,000. The company sold common stock and pre-funded warrants, including a separate sale of pre-funded warrants to purchase up to 17,618,041 shares for approximately $25,000,000. The earlier placement raised $60 million. The purchase price per pre-funded warrant in the second placement was $1.419, and the warrants carry an exercise price of $0.001 per share, are exercisable at any time and do not expire.
The financings closed on August 13, 2025, and X4 reported that on a fully-diluted basis shares outstanding will be approximately 87.2 million. The securities were sold in private transactions under exemptions from registration (Regulation D) and the company agreed to file a registration statement to register the resale of the issued shares and shares underlying the pre-funded warrants. Copies of the agreements and a press release are filed as exhibits.
X4 Pharmaceuticals ha completato due collocamenti privati collegati che hanno raccolto proventi lordi complessivi pari a $85,000,000. La societ脿 ha venduto azioni ordinarie e warrant prefinanziati, inclusa una vendita separata di warrant prefinanziati per l'acquisto di fino a 17,618,041 azioni per circa $25,000,000. Il collocamento precedente aveva raccolto $60 million. Il prezzo di acquisto per ciascun warrant prefinanziato nel secondo collocamento 猫 stato di $1.419; i warrant hanno un prezzo di esercizio di $0.001 per azione, sono esercitabili in qualsiasi momento e non scadono.
I finanziamenti si sono chiusi il 13 agosto 2025 e X4 ha riportato che, su base completamente diluita, le azioni in circolazione saranno circa 87.2 million. I titoli sono stati venduti in transazioni private ai sensi delle esenzioni dalla registrazione (Regulation D) e la societ脿 si 猫 impegnata a depositare una dichiarazione di registrazione per registrare la rivendita delle azioni emesse e delle azioni sottostanti i warrant prefinanziati. Copie degli accordi e un comunicato stampa sono depositati come allegati.
X4 Pharmaceuticals complet贸 dos colocaciones privadas relacionadas que recaudaron un total bruto agregado de $85,000,000. La compa帽铆a vendi贸 acciones ordinarias y warrants prefinanciados, incluida una venta separada de warrants prefinanciados para comprar hasta 17,618,041 acciones por aproximadamente $25,000,000. La colocaci贸n anterior recaud贸 $60 million. El precio de compra por warrant prefinanciado en la segunda colocaci贸n fue de $1.419, y los warrants tienen un precio de ejercicio de $0.001 por acci贸n, son ejercitables en cualquier momento y no vencen.
Los financiamientos se cerraron el 13 de agosto de 2025, y X4 inform贸 que, sobre una base totalmente diluida, las acciones en circulaci贸n ser谩n aproximadamente 87.2 million. Los valores se vendieron en transacciones privadas bajo exenciones de registro (Regulation D) y la compa帽铆a acept贸 presentar una declaraci贸n de registro para inscribir la reventa de las acciones emitidas y de las acciones subyacentes a los warrants prefinanciados. Copias de los acuerdos y un comunicado de prensa est谩n presentados como anexos.
X4 Pharmaceuticals電� 齑� 85,000,000雼煬鞚� 齑濎垬鞚奠潉 臁半嫭頃橂姅 霊� 瓯挫潣 甏�霠� 靷 鞚胳垬毳� 鞕勲頄堨姷雼堧嫟. 須岇偓電� 氤错喌欤检檧 頂勲Μ韼�霐旊摐 鞗岆煱韸鸽ゼ 毵り皝頄堨溂氅�, 攴胳 氤勲弰 毵り皝鞚� 韱淀暣 斓滊寑 17,618,041欤茧ゼ 鞎� $25,000,000鞐� 甑Г頃� 靾� 鞛堧姅 頂勲Μ韼�霐旊摐 鞗岆煱韸鸽ゼ 韺愲Г頄堨姷雼堧嫟. 鞚挫爠 鞚胳垬電� $60 million鞚� 臁半嫭頄堨姷雼堧嫟. 霊� 氩堨Ц 鞚胳垬鞐愳劀 頂勲Μ韼�霐旊摐 鞗岆煱韸胳潣 1臧滊嫻 毵れ瀰 臧�瓴╈潃 $1.419鞓�瓿�, 鞗岆煱韸胳潣 頄夓偓臧�瓴╈潃 欤茧嫻 $0.001鞚措┌ 鞏胳牅霌犾 頄夓偓頃� 靾� 鞛堦碃 毵岆霅橃 鞎婌姷雼堧嫟.
鞚� 鞛愱笀 臁半嫭鞚� 2025雲� 8鞗� 13鞚�鞐� 毵堦皭霅橃棃鞙茧┌, X4電� 鞕勳爠 頋劃 旮办鞙茧 鞙犿喌 欤检嫕 靾橁皜 鞎� 87.2 million欤缄皜 霅� 瓴冹澊霛缄碃 氤搓碃頄堨姷雼堧嫟. 歃濌秾鞚� 霌彪 氅挫牅(Regulation D)鞐� 霐半ジ 靷爜 瓯半灅搿� 韺愲Г霅橃棃瓿�, 須岇偓電� 氚滍枆霅� 欤检嫕 氚� 頂勲Μ韼�霐旊摐 鞗岆煱韸胳棎 霐半ジ 欤检嫕鞚� 鞛寪毵るゼ 霌彪頃橁赴 鞙勴暣 霌彪氇呾劯靹滊ゼ 鞝滌稖頃橁赴搿� 頃╈潣頄堨姷雼堧嫟. 瓿勳暯靹� 靷掣瓿� 氤措弰鞛愲電� 歃濍箼靹滊搿� 鞝滌稖霅橃柎 鞛堨姷雼堧嫟.
X4 Pharmaceuticals a r茅alis茅 deux placements priv茅s li茅s qui ont permis de lever un produit brut global de 85 000 000 $. La soci茅t茅 a vendu des actions ordinaires et des warrants pr茅financ茅s, y compris une vente distincte de warrants pr茅financ茅s donnant droit 脿 l'achat jusqu'脿 17,618,041 actions pour environ 25 000 000 $. Le placement ant茅rieur avait lev茅 60 million $. Le prix d'achat par warrant pr茅financ茅 lors du deuxi猫me placement 茅tait de $1.419 ; les warrants ont un prix d'exercice de $0.001 par action, sont exer莽ables 脿 tout moment et n'expirent pas.
Les financements ont 茅t茅 cl么tur茅s le 13 ao没t 2025, et X4 a d茅clar茅 que, sur une base totalement dilu茅e, les actions en circulation seront d'environ 87.2 million. Les titres ont 茅t茅 vendus dans des transactions priv茅es en vertu d'exemptions d'enregistrement (Regulation D) et la soci茅t茅 s'est engag茅e 脿 d茅poser une d茅claration d'enregistrement pour enregistrer la revente des actions 茅mises et des actions sous-jacentes aux warrants pr茅financ茅s. Des copies des accords et un communiqu茅 de presse sont d茅pos茅s en tant que pi猫ces.
X4 Pharmaceuticals hat zwei zusammenh盲ngende Privatplatzierungen abgeschlossen, die zusammen Bruttoerl枚se von $85,000,000 einbrachten. Das Unternehmen verkaufte Stammaktien und vorfinanzierte Warrants, darunter einen separaten Verkauf vorfinanzierter Warrants, die zum Kauf von bis zu 17,618,041 Aktien f眉r etwa $25,000,000 berechtigen. Die fr眉here Platzierung erzielte $60 million. Der Kaufpreis pro vorfinanziertem Warrant in der zweiten Platzierung betrug $1.419; die Warrants haben einen Aus眉bungspreis von $0.001 je Aktie, sind jederzeit aus眉bbar und laufen nicht ab.
Die Finanzierungen wurden am 13. August 2025 abgeschlossen, und X4 gab an, dass die ausstehenden Aktien auf voll verw盲sserter Basis etwa 87.2 million betragen werden. Die Wertpapiere wurden in privaten Transaktionen unter Ausnahmen von der Registrierung (Regulation D) verkauft, und das Unternehmen verpflichtete sich, eine Registrierungserkl盲rung einzureichen, um den Wiederverkauf der ausgegebenen Aktien und der den vorfinanzierten Warrants zugrundeliegenden Aktien zu registrieren. Kopien der Vereinbarungen und eine Pressemitteilung sind als Anlagen eingereicht.
- Aggregate gross proceeds of $85,000,000 were raised through two private placements.
- Pre-funded warrants sold are exercisable at $0.001 and do not expire, offering flexibility for warrant holders.
- Registration Rights Agreement executed and exhibits filed, indicating the company will register resale of the issued shares and underlying warrants.
- Fully-diluted shares outstanding will be approximately 87.2 million, reflecting dilution to existing shareholders.
- Pre-funded warrants issued at a $0.001 exercise price are highly dilutive when exercised, increasing potential share issuance.
Insights
TL;DR: X4 raised significant liquidity鈥�$85M鈥攖hrough private placements, using pre-funded warrants and registration rights to enable future resale.
The company executed two private placements totaling aggregate gross proceeds of $85,000,000, including a second placement selling pre-funded warrants to purchase up to 17,618,041 shares for approximately $25,000,000. The pre-funded warrants carry a $0.001 exercise price and are non-expiring. Transactions were completed under Regulation D exemptions with investors representing they are accredited; X4 agreed to file a registration statement to permit resale. These are material financing events that increase liquidity and provide registered resale mechanics, as reflected by the filed Securities Purchase Agreement and Registration Rights Agreement exhibits.
TL;DR: The financings materially increase capital but expand fully-diluted share count to ~87.2M; registration rights aim to enable future liquidity for investors.
The filings show the first private placement of $60 million plus a second placement of approximately $25,000,000 in pre-funded warrants, closed on August 13, 2025. The transaction structure鈥攑re-funded warrants exercisable at $0.001 with no expiration鈥攚ill affect capitalization and produce a reported fully-diluted share count of about 87.2 million. X4 has contractual registration rights and has filed related agreements as exhibits, which is standard to enable resale after registration. The company included customary forward-looking statement qualifiers regarding closing conditions and filing timelines.
X4 Pharmaceuticals ha completato due collocamenti privati collegati che hanno raccolto proventi lordi complessivi pari a $85,000,000. La societ脿 ha venduto azioni ordinarie e warrant prefinanziati, inclusa una vendita separata di warrant prefinanziati per l'acquisto di fino a 17,618,041 azioni per circa $25,000,000. Il collocamento precedente aveva raccolto $60 million. Il prezzo di acquisto per ciascun warrant prefinanziato nel secondo collocamento 猫 stato di $1.419; i warrant hanno un prezzo di esercizio di $0.001 per azione, sono esercitabili in qualsiasi momento e non scadono.
I finanziamenti si sono chiusi il 13 agosto 2025 e X4 ha riportato che, su base completamente diluita, le azioni in circolazione saranno circa 87.2 million. I titoli sono stati venduti in transazioni private ai sensi delle esenzioni dalla registrazione (Regulation D) e la societ脿 si 猫 impegnata a depositare una dichiarazione di registrazione per registrare la rivendita delle azioni emesse e delle azioni sottostanti i warrant prefinanziati. Copie degli accordi e un comunicato stampa sono depositati come allegati.
X4 Pharmaceuticals complet贸 dos colocaciones privadas relacionadas que recaudaron un total bruto agregado de $85,000,000. La compa帽铆a vendi贸 acciones ordinarias y warrants prefinanciados, incluida una venta separada de warrants prefinanciados para comprar hasta 17,618,041 acciones por aproximadamente $25,000,000. La colocaci贸n anterior recaud贸 $60 million. El precio de compra por warrant prefinanciado en la segunda colocaci贸n fue de $1.419, y los warrants tienen un precio de ejercicio de $0.001 por acci贸n, son ejercitables en cualquier momento y no vencen.
Los financiamientos se cerraron el 13 de agosto de 2025, y X4 inform贸 que, sobre una base totalmente diluida, las acciones en circulaci贸n ser谩n aproximadamente 87.2 million. Los valores se vendieron en transacciones privadas bajo exenciones de registro (Regulation D) y la compa帽铆a acept贸 presentar una declaraci贸n de registro para inscribir la reventa de las acciones emitidas y de las acciones subyacentes a los warrants prefinanciados. Copias de los acuerdos y un comunicado de prensa est谩n presentados como anexos.
X4 Pharmaceuticals電� 齑� 85,000,000雼煬鞚� 齑濎垬鞚奠潉 臁半嫭頃橂姅 霊� 瓯挫潣 甏�霠� 靷 鞚胳垬毳� 鞕勲頄堨姷雼堧嫟. 須岇偓電� 氤错喌欤检檧 頂勲Μ韼�霐旊摐 鞗岆煱韸鸽ゼ 毵り皝頄堨溂氅�, 攴胳 氤勲弰 毵り皝鞚� 韱淀暣 斓滊寑 17,618,041欤茧ゼ 鞎� $25,000,000鞐� 甑Г頃� 靾� 鞛堧姅 頂勲Μ韼�霐旊摐 鞗岆煱韸鸽ゼ 韺愲Г頄堨姷雼堧嫟. 鞚挫爠 鞚胳垬電� $60 million鞚� 臁半嫭頄堨姷雼堧嫟. 霊� 氩堨Ц 鞚胳垬鞐愳劀 頂勲Μ韼�霐旊摐 鞗岆煱韸胳潣 1臧滊嫻 毵れ瀰 臧�瓴╈潃 $1.419鞓�瓿�, 鞗岆煱韸胳潣 頄夓偓臧�瓴╈潃 欤茧嫻 $0.001鞚措┌ 鞏胳牅霌犾 頄夓偓頃� 靾� 鞛堦碃 毵岆霅橃 鞎婌姷雼堧嫟.
鞚� 鞛愱笀 臁半嫭鞚� 2025雲� 8鞗� 13鞚�鞐� 毵堦皭霅橃棃鞙茧┌, X4電� 鞕勳爠 頋劃 旮办鞙茧 鞙犿喌 欤检嫕 靾橁皜 鞎� 87.2 million欤缄皜 霅� 瓴冹澊霛缄碃 氤搓碃頄堨姷雼堧嫟. 歃濌秾鞚� 霌彪 氅挫牅(Regulation D)鞐� 霐半ジ 靷爜 瓯半灅搿� 韺愲Г霅橃棃瓿�, 須岇偓電� 氚滍枆霅� 欤检嫕 氚� 頂勲Μ韼�霐旊摐 鞗岆煱韸胳棎 霐半ジ 欤检嫕鞚� 鞛寪毵るゼ 霌彪頃橁赴 鞙勴暣 霌彪氇呾劯靹滊ゼ 鞝滌稖頃橁赴搿� 頃╈潣頄堨姷雼堧嫟. 瓿勳暯靹� 靷掣瓿� 氤措弰鞛愲電� 歃濍箼靹滊搿� 鞝滌稖霅橃柎 鞛堨姷雼堧嫟.
X4 Pharmaceuticals a r茅alis茅 deux placements priv茅s li茅s qui ont permis de lever un produit brut global de 85 000 000 $. La soci茅t茅 a vendu des actions ordinaires et des warrants pr茅financ茅s, y compris une vente distincte de warrants pr茅financ茅s donnant droit 脿 l'achat jusqu'脿 17,618,041 actions pour environ 25 000 000 $. Le placement ant茅rieur avait lev茅 60 million $. Le prix d'achat par warrant pr茅financ茅 lors du deuxi猫me placement 茅tait de $1.419 ; les warrants ont un prix d'exercice de $0.001 par action, sont exer莽ables 脿 tout moment et n'expirent pas.
Les financements ont 茅t茅 cl么tur茅s le 13 ao没t 2025, et X4 a d茅clar茅 que, sur une base totalement dilu茅e, les actions en circulation seront d'environ 87.2 million. Les titres ont 茅t茅 vendus dans des transactions priv茅es en vertu d'exemptions d'enregistrement (Regulation D) et la soci茅t茅 s'est engag茅e 脿 d茅poser une d茅claration d'enregistrement pour enregistrer la revente des actions 茅mises et des actions sous-jacentes aux warrants pr茅financ茅s. Des copies des accords et un communiqu茅 de presse sont d茅pos茅s en tant que pi猫ces.
X4 Pharmaceuticals hat zwei zusammenh盲ngende Privatplatzierungen abgeschlossen, die zusammen Bruttoerl枚se von $85,000,000 einbrachten. Das Unternehmen verkaufte Stammaktien und vorfinanzierte Warrants, darunter einen separaten Verkauf vorfinanzierter Warrants, die zum Kauf von bis zu 17,618,041 Aktien f眉r etwa $25,000,000 berechtigen. Die fr眉here Platzierung erzielte $60 million. Der Kaufpreis pro vorfinanziertem Warrant in der zweiten Platzierung betrug $1.419; die Warrants haben einen Aus眉bungspreis von $0.001 je Aktie, sind jederzeit aus眉bbar und laufen nicht ab.
Die Finanzierungen wurden am 13. August 2025 abgeschlossen, und X4 gab an, dass die ausstehenden Aktien auf voll verw盲sserter Basis etwa 87.2 million betragen werden. Die Wertpapiere wurden in privaten Transaktionen unter Ausnahmen von der Registrierung (Regulation D) verkauft, und das Unternehmen verpflichtete sich, eine Registrierungserkl盲rung einzureichen, um den Wiederverkauf der ausgegebenen Aktien und der den vorfinanzierten Warrants zugrundeliegenden Aktien zu registrieren. Kopien der Vereinbarungen und eine Pressemitteilung sind als Anlagen eingereicht.
FAQ
What did X4 (XFOR) announce in this 8-K?
How were the securities structured in X4's financing?
Will X4 register the resale of the securities?
Under what exemption were the securities sold?
What is the reported impact on share count?
